Activist DOMA Escalates Proxy Fight, Urges Pacira Sale Amid 'Existential' Patent Risk

summarizeSummary

Activist investor DOMA Perpetual Capital Management has released definitive additional proxy materials, criticizing Pacira's management for underperformance and patent risk, and pushing for a strategic sale of the company.

check_boxKey Events

• Activist Escalates Proxy Battle

  DOMA Perpetual Capital Management, a 7.5% shareholder, filed definitive additional proxy materials, intensifying its campaign to elect three director nominees at the upcoming June 9, 2026 annual meeting.

• Accusations of Underperformance

  DOMA alleges 'gross and persistent underperformance' by current management and the board, citing significant negative total shareholder returns over multiple periods, including -64% over five years and -28% since the current CEO took over.

• Concerns Over EXPAREL Patent Risk

  The activist investor claims the board is 'grossly mismanaging' the patent risk for EXPAREL, Pacira's core asset, and warns that further legal losses could be 'catastrophic' without a clear contingency plan.

• Call for Strategic Alternatives and Sale

  DOMA advocates for a board-supervised process to explore strategic alternatives, including a potential sale of the company, as the 'best, safest path' to protect and generate shareholder value.

auto_awesomeAnalysis

Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake, has intensified its proxy battle by issuing a letter to shareholders. DOMA accuses current management and the board of persistent underperformance and gross negligence in managing the critical EXPAREL patent risk, which they argue poses an existential threat to the company. They advocate for a strategic review, including a potential sale, to protect shareholder value, directly challenging the company's current strategy and executive compensation. This filing is a critical escalation ahead of the June 9, 2026 annual meeting, where shareholders will vote on DOMA's director nominees.